Search Result

Results for "

gastric inhibitory peptide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dipeptidyl Peptidase (1) GLP Receptor (3) Insulin Receptor (13)
By Research Areas:	Endocrinology (4) Metabolic Disease (13)

Inhibitors & Agonists

Peptides

Targets Recommended: Macrophage migration inhibitory factor (MIF) Formyl Peptide Receptor (FPR) Connective Peptide Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) RXFP Receptor CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3579

Gastric Inhibitory Peptide, porcine GIP (1-42), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose metabolism .

HY-P0276

GIP, human 1 Publications Verification gastric inhibitory peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P0276A

GIP, human TFA 1 Publications Verification gastric inhibitory peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P3580A

*Acetyl Gastric* Inhibitory Peptide (human) (TFA)** Human N-acetyl GIP TFA	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .

HY-P3584A

(Pro3) GIP, human TFA (Pro3) gastric inhibitory peptide, human TFA	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .

HY-103545

GIP (1-39) gastric inhibitory peptide (1-39) (porcine)	Insulin Receptor	Metabolic Disease
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca ²⁺ concentration ([Ca ²⁺]_i), and capable of enhancing exocytosis .

HY-P3577

*[Tyr0] Gastric* Inhibitory Peptide (23-42), human**	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-P3580

*Acetyl Gastric* Inhibitory Peptide (human)** Human N-acetyl GIP	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .

HY-P3584

(Pro3) GIP, human (Pro3) gastric inhibitory peptide, human	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with K_i/ K_d values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes .

HY-P10959

Macupatide LY3532226	Insulin Receptor	Metabolic Disease
Macupatide is a gastric inhibitory peptide (GIP) receptor agonist used in anti-diabetic research .

HY-P10952

Astepatide	Insulin Receptor GLP Receptor	Metabolic Disease
Astepatide is a gastric inhibitory peptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in anti-diabetic research .

HY-P10591

Olatorepatide Olatorepatidum	Insulin Receptor GLP Receptor	Metabolic Disease
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .

HY-E70397A

Dipeptidyl Peptidase IV, Porcine Kidney DPP-IV, Porcine Kidney	Dipeptidyl Peptidase	Metabolic Disease
Dipeptidyl Peptidase IV, Porcine Kidney (DPP-IV, Porcine Kidney) is a serine aminopeptidase with multiple physiological roles. Dipeptidyl Peptidase IV, Porcine Kidney hydrolyses gastric inhibitory peptide (GIP) and glucagon-like peptide 1 (GLP-1), the most important insulin-releasing hormones (incretins) of the enteroinsular axis .

HY-P3578

Gastric Inhibitory Polypeptide (1-30), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Polypeptide (1-30), porcine lacks the C-terminal 12 amino acid residues of natural gastric inhibitory polypeptide (GIP), exhibits biologic activity by potentiating the release of insulin and somatostatin .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

Cat. No.	Product Name	Target	Research Area

HY-P3579

Gastric Inhibitory Peptide, porcine GIP (1-42), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Peptide, porcine is a glucose-dependent insulinotropic polypeptide, is a 42 amino acid intestinal hormone with effects on fat and glucose metabolism .

HY-P0276

GIP, human 1 Publications Verification gastric inhibitory peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P0276A

GIP, human TFA 1 Publications Verification gastric inhibitory peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P3580A

*Acetyl Gastric* Inhibitory Peptide (human) (TFA)** Human N-acetyl GIP TFA	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .

HY-P3584A

(Pro3) GIP, human TFA (Pro3) gastric inhibitory peptide, human TFA	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .

HY-103545

GIP (1-39) gastric inhibitory peptide (1-39) (porcine)	Insulin Receptor	Metabolic Disease
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca ²⁺ concentration ([Ca ²⁺]_i), and capable of enhancing exocytosis .

HY-P3577

*[Tyr0] Gastric* Inhibitory Peptide (23-42), human**	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-P3580

*Acetyl Gastric* Inhibitory Peptide (human)** Human N-acetyl GIP	Insulin Receptor	Metabolic Disease Endocrinology
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .

HY-P3584

(Pro3) GIP, human (Pro3) gastric inhibitory peptide, human	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with K_i/ K_d values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes .

HY-P10959

Macupatide LY3532226	Insulin Receptor	Metabolic Disease
Macupatide is a gastric inhibitory peptide (GIP) receptor agonist used in anti-diabetic research .

HY-P10952

Astepatide	Insulin Receptor GLP Receptor	Metabolic Disease
Astepatide is a gastric inhibitory peptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in anti-diabetic research .

HY-P10591

Olatorepatide Olatorepatidum	Insulin Receptor GLP Receptor	Metabolic Disease
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .

HY-P5390

GIP, rat	Peptides	Others
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)

HY-P5390A

GIP, rat TFA	Peptides	Others
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.

HY-P3578

Gastric Inhibitory Polypeptide (1-30), porcine	Insulin Receptor	Endocrinology
Gastric Inhibitory Polypeptide (1-30), porcine lacks the C-terminal 12 amino acid residues of natural gastric inhibitory polypeptide (GIP), exhibits biologic activity by potentiating the release of insulin and somatostatin .

HY-P0165B

Taspoglutide acetate ITM077 acetate; R1583 acetate; BIM51077 acetate	GLP Receptor	Metabolic Disease
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an K_i value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC₅₀ = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.